Citadel Advisors
APVO icon

Citadel Advisors’s Aptevo Therapeutics APVO Stock Holding History

Citadel Advisors’s Portfolio APVO Stock Details APVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8
Closed -$20.1K – 14451
2024
Q3 		$20.1K Buy
+8
New +$36.8K ﹤0.01% 12767
2024
Q1 		– Hold
0
– -$47.4K – 14508
2023
Q4 		– Hold
0
– – – 11832
2023
Q3 		– Hold
0
– -$18.7K – 14242
2023
Q2 		– Hold
0
– – – 12787
2023
Q1 		– Hold
0
– -$97.6K – 14670
2022
Q4 		– Hold
0
– – – 11254
2022
Q3 		– Hold
0
– – – 11609
2018
Q3 		– Hold
0
– -$61K – 9169
2018
Q2 		– Hold
0
– – – 8395
2018
Q1 		– Hold
0
– – – 7609
2017
Q4 		– Hold
0
– – – 7611

Other funds holding APVO

VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CFFP
Center for Financial Planning Southfied, Michigan $1.07B AUM 18.98% 1-Year Est. Return

Citadel Advisors's APVO Position: Q4 2024 in Review

Citadel Advisors sold out of Aptevo Therapeutics (APVO) in Q4 2024, closing a stake of 8 shares — an estimated $20.1K sold.

Citadel Advisors first reported a position in APVO in Q3 2024 and held it in 1 quarter. The position peaked at $20.1K in Q3 2024. 7 funds tracked by Wall St. Rank hold APVO as of Q4 2024.

  • Citadel Advisors reported no remaining Aptevo Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Citadel Advisors sold 8 Aptevo Therapeutics shares in Q4 2024, an estimated $20.1K.
  • Citadel Advisors first reported a position in Aptevo Therapeutics in Q3 2024 and held it in 1 quarter.
  • Citadel Advisors's Aptevo Therapeutics position peaked at $20.1K in Q3 2024.
  • 7 funds tracked by Wall St. Rank held Aptevo Therapeutics as of Q4 2024.

Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.